secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001493152-24-051835
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech officers Equels and Rodino voluntarily forego 2024 cash bonuses to fund Ampligen R&D
--------------------------------------------------------------------------------

- CEO Thomas K. Equels and Peter W. Rodino III notified the Compensation Committee they will forgo their 2024 cash bonuses.
- The voluntary waiver is intended to help AIM focus financial resources on Ampligen R&D activities.
- The Compensation Committee then determined that neither will receive a cash bonus for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315224051835/0001493152-24-051835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315224051835/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer